Clarence Moore, PharmD, BCPS, BCOP, assistant professor at Shenandoah University in Ashburn, Virginia, discusses how stem cell therapy and heart health can help patients manage beta thalassemia.
Transcript
How has the emergence of stem cell therapy changed the lives of people with beta thalassemia?
Stem cell therapy is offering a cure. So, with us really looking at stem cell therapy, with the more and more work [being done], we'll be able to see that these individuals will no longer have to experience this lifelong disease, and they could potentially be cured.
What is the importance of heart health for patients, especially those with beta thalassemia major?
Heart health is very important. When you look at one of the largest comorbidities that is associated with [beta thalassemia], it is heart health. You can see some cardiomyopathy develop. So, maintaining heart health is very important in decreasing the morbidity and mortality associated with the disease state.
What is the importance conducting blood tests to determine beta thalassemia types in young children?
I think that it's very important. Knowing upfront what disease or what type of beta thalassemia that these individuals may have is going to be vital for us to manage it. And if we're able to potentially manage that at the earlier stage, we could potentially have better outcomes in the future.
New Study Finds Risk Groups, Outpatient Care Barriers in Chronic Liver Disease
November 20th 2024Patients with chronic liver disease who were unable to establish care were 85% more likely to require recurrent hospitalizations. This group included a disproportionate number of women and individuals with physical limitations affecting their health.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM
November 19th 2024The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM).
Read More